Activation of androgen receptors with low dose non-masculinizing

Details Activation of androgen receptors with low dose non-masculinizing Activation of androgen receptors with low dose non-masculinizing

1994-07-29

1996-08-13

Nutter, Nathan M.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Cyclopentanohydrophenanthrene ring system doai

514170, 514177, 514179, A61K 3156, A01N 4500

Patent

active

055456340

ABSTRACT:
A method of treatment or prevention of breast and endometrial cancer, osteoporosis and endometriosis in susceptible warm-blooded animals comprising administering a low dose. Of a progestin or other steroid derivative having androgenic activity and low masculinizing activity. Pharmaceutical compositions useful for such treatment and pharmaceutical kits containing such compositions are disclosed. An in vitro assay permitting specific measurements of androgenic activity of potentially useful compounds is also disclosed.

REFERENCES:
patent: 3773919 (1973-11-01), Boswell et al.
patent: 4071622 (1978-01-01), Johnson
patent: 4472382 (1984-09-01), Labrie
patent: 4522831 (1985-06-01), Chatterton, Jr.
patent: 4659695 (1987-04-01), Labrie
patent: 4760053 (1988-07-01), Labrie
patent: 4775660 (1988-10-01), Labrie
patent: 4775661 (1988-10-01), Labrie
patent: 4789726 (1988-12-01), Hutchinson
patent: 4826831 (1989-05-01), Plunkett et al.
patent: 5043331 (1991-08-01), Hirvonen et al.
Poulin et al "Androgens inhibit basal and estrogen-induced cell proliferation in the ZR-75-1 human breast cancer cell line" Breast Cancer Research and Treatment 12:213-225 (1988).
Poulin et al "Androgens and glucocortizoid receptor-mediated inhibition of cell proliferation by medroxyprogesterone acetate in ZR-75-1 human breast cancer cells" Breast Cancer Research and Treatment 13:161-172 (1989).
Poulin et al "Down-Regulation of Estrogen Receptors by Androgens in the ZR-75-1 Human Breast Cancer Cell Line" Endocrinology vol. 125, No. 1, 392-399 (1989).
Young et al "Binding of medroxyprogesterone acetate in human breast cancer" Am. J. Obstet. Gynecol. Jun. 1, 1980, vol. 137, No. 3 pp. 284-292.
J anne et al "Steroid Receptors and Hormone Action: Physiological and Synthetic Androgens and Progestins Can Mediate Inappropriate Biological Effects" Pharmacological Reviews, vol. 36, No. 2, 1984, pp. 35S-42S.
Adair, Surg. Gynecol. Obstet. 84: 719-722, 1947.
Adair et al., JAMA 140: 1193-2000, 1949.
Adair and Herrmann, Ann. Surg. 123: 1023-1035, 1946.
Albright, et al., In: The Parathyroid Glands & Metabolic Bone Disease, Williams & Williams Co: Baltimore, pp. 145-204 (1948).
Allegra et al., Cancer Res. 39:1447-1454, 1979.
Aloia et al., Arch. Int. Med. 143:1700-1704, 1983.
Aloia et al., Metabolism 30:1076-1079 (1981).
Asselin et al., Cancer Res. 40:1612-1622 (1980).
Baran et al., Calif. Tissue Res. 26:103-106, 1978.
Blossey et al., Cancer 54: 1208-1215, 1984.
Blumenschein, Semin. Oncol. 10: 7-10, 1983.
Bryan et al., Cancer 54: 2436-2440, 1984.
Bullock et al., Endocrinology 103: 1768-1782, 1978.
Centola, Cancer Res. 45: 6264-6267, 1985.
Cheng and Prusoff, Biochem. Pharmacol. 22:3099-3108, 1973.
Chessnut et al. Metabolism 26: 267-277, 1977.
Chessnut et al., Metabolism 32:571-580, 1983.
Clavel et al., Eur J. Cancer Clin. Oncol. 18:821-826, 1982.
Colvard, et al., Proc. Natl. Acad. Sci. 86: 854-857, 1989.
Cooperative Breast Cancer Group, JAMA 188, 1069-1072, 1964.
Cremonicini et al., Acta. Eur. Fertil. 7:248-314, 1976.
Cusan et al., J. Am. Acad. Dermatol. 23:462-469, 1990.
Dauvois & Labrie, Cancer Res. 51:3131-3151 (1991).
Dauvois, et al., Breast Cancer. Res. Treatment 14:299-306 (1989).
Dequaker & Geusens, Acta Endocrimol 271 (Suppl):45-52, 1985.
The Merck Index, (1989) p. 909, No. 5677; p. 910, No. 5687.
Deutsch et al., Int. J. Gynecol. Obstet. 25: 217-222, 1987.
Dhem, A., Ars-Piret N., Waterschoot MP (9180) Curr. Med. Res. Opin. 6: 606-613.
Dickson & Lippman, Endocr. Rev. 8:29-43, 1987181, 1975.
Dixon et al., Clinical Endocrinology 30: 271-277, 1989.
Earl et al., Clin. Oncol. 10:103-109, 1984.
Ehrlich et al., Am. J. Obstet Gynecol. 158: 797-807, 1988.
Engel et al., Cancer Res. 38: 3352-3364, 1978.
Engelsman et al., British J. Cancer 30: 177-181, 1975.
Ericksen et al., Science 241: 84-86, 1988.
Ferriman & Gallwey, J.P. Clin Endocrimol. Metab 21: 1440-1447, 1961.
Finkelstein et al., Ann. Int. Med. 106:354-361 (1987).
Finkelstein et al., J. Clin. Endocr. Metab. 69:776-783, 1989.
Francis, et al., Bone 7: 261-268 (1986).
Foresta et al., Horm. Metab. Res. 15:206-207, 1983.
Foresta et al., Horm. Metab. Res. 15:56-57, 1983.
Goldenberg et al., JAMA 223: 1267-1268, 1973.
Greenspan et al., Ann. Int. Med. 110:526-531, 1989.
Greenspan et al., Ann Int. Med. 104:777-782, 1986.
Haller and Glick, Semin. Oncol. 13: 2-8, 1986.
Hamblen, South Med. J. 50: 743-750, 1987.
Harrison et al., Metabolism 20:1107-1118, 1971.
Hollo et al., Lancet 2:1205, 1971.
Hollo et al., Lancet 1: 1357, 1976.
Hilf. R., Anabolic-Androgenic Steroids and Experimental Tumors In: Handbook of Experimental Pharmacology, vol. 43, Anabolic-Androgenic Steroids, Springer-Verlag, Berlin 43 (1976) 191-210 and p. 725.
Hollo and Feher, Acta. Med. Hung. 20: 233, 1964.
Hollo et al., Acta Med. Hung. 27: 155-160, 1970.
Hortobagyi et al., Breast Cancer Res. Treatm. 5: 321-326, 1985.
Horwitz, J. Steroid Biochem. 27: 447-457, 1987.
Horwitz et al., Cancer Res. 38: 2434-2439, 1978.
Janne and Bardin, Pharmacol. Rev. 36: 35S-42S, 1984.
Johnson et al. Semin. Oncol. 13(suppl):15-19, 1986.
Kennedy et al., Cancer 21: 197-201, 197.
Kennedy, Hormone Therapy in Cancer Geriatrics 25: 106-112, 1970.
Klijn et al., J. Steroid Biochem. 20: 1381, 1984.
Komm, et al., Science 241: 81-84, 1988.
Krabbe et al., Arch. Dis. Child. 54, 950-953, 1979.
Krabbe et al., Arch. Pediat. Scand. 73:750-755, 1984.
Kramer, C. Y., Biometrics 12:307-310, 1956.
Labrie, C. et al., J. Steroid Biochem. 28: 379-384, 1987.
Labrie et al., Fertil Steril 28: 1104-1112, 1977.
Labrie, et al., Mol. Cell Endocrinol. 68: 169-179, 1990.
LeMay, et al., Fertil. Steril. 31:29-34, 1979.
Lafferty et al., Ann. J. Med. 36: 514-528, 1964.
Lamb, Am. J. Sports Medicine 121, 31-38, 1984.
Lea et al., Cancer Res. 49: 7162-7167, 1989.
Lippman, et al., Cancer Res. 36: 4610-4618, 1976.
Lippman et al., Cancer 38: 868-874, 1976.
Lippman, Semin. Oncol. 10 (Suppl. 4): 11-19, 1983.
Lucas, Obstet. Gynecol. Surv. 29: 507-528, 1974.
Luthy et al., J. Steroid Biochem. 31: 845-852, 1988.
Mack et al., N. Engl. J. Medicine 294: 1262-1267, 1976.
Maass, H. et al. J. Ster. Biochem. 5: 734-749.
MacLaughlin and Richardson, J. Steroid Biochem. 10: 371-377.
Manni et al., Cancer 48: 2507-2509, 1981.
Manni, Endocr., Rev. 7: 89-94.
Mattsson, Breast Cancer Res. Treatm. 3: 231-235, 1983.
McDermott & Kidd, End. Rev. 8:377-390, 1987.
Muechler and Kohler, Gynenol. Invest. 8: 104, 1988.
Miller et al., Eur. J. Oncol. 21: 539-542, 1985.
Nathanson, Rec. Prob. Horm. Res. 1: 261-291, 1947.
Need et al., Mineral Electrolyte Metabolism 11:35, 1985.
Need. Clin. Orthop. 225: 273, 1987.
Nicholson et al., J. Steroid Biochem. 23: 843-848, 1985.
Nicholson et al., Brit. J. Cancer 39: 268-273, 1979.
Nordin et al., J. Clin. Endocr. Metab. 60: 651, 1985.
Odell and Swerdcoff, West. J. Med. 124:446-475.
Ogata et al., Endocrinology 87:421, 1970.
Ojasso et al., J. Steroid Biochem 27: 255-269, 1987.
Perez-Palacios et al., J. Steroid Biochem. 15: 125-130, 1981.
Perez-Palacois et al., J. Steroid Biochem. 19: 1729-1735, 1983.
Plante et al., J. Steroid Biochem. 31: 61-64, 1988.
Podratz et al., Obstet. Gynecol. 66: 106-110, 1985.
Poulin & LaBrie, Cancer Res. 46: 4933-4937, 1986.
Poulin et al., Breast Cancer Res. Treatm. 13:161-172, 1989.
Poulin et al., Breast Cancer Research Treatm. 12: 213-225, 1988.
Poulin et al., Breast Cancer Res. Treatment 13:265-276, 1989.
Poulin et al., Endocrinology 125: 392-399, 1989.
Poyet and Labrie, Mol. Cell Endocrinol. 42: 283-288, 1985.
Poyet, et al., The Prostate 9: 237-246, 1986.
Preston, Obstet, Gynecol. 2: 152-157, 1965.
Pridjian et al., J. Steroid Biochem. 26: 313-319.
Puche & Rosmano, Calif. Tissue Res. 4:39-47, 1969.
Raynaud et al. Steroid Hormones, Agonists and Antagonists In: Mechanisms of Steroid Action, MacMillan Press, London, pp. 143-157 (1981).
Raynaud & Ojasso In: Innovative Approaches in Drug Research, Elsevier Sci. Publishers, Amsterdam, pp. 47-72, 1986.
Raynaud & Ojasso, J. Steroid Biochem. 25:811-833, 1986.
Raynaud, et al., J. Steroid Biochem 12: 143-157.
Rendina et al., Europ. J. Obstet Gynecol. Reprod. Biol. 17: 285-291, 1984.
Riggs et al., J. Clin. Invest. 67:328-33

Affiliated with

Also associated with

Rating

Activation of androgen receptors with low dose non-masculinizing does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Activation of androgen receptors with low dose non-masculinizing, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Activation of androgen receptors with low dose non-masculinizing will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1048036